Intestinal Lymphangiectasia

Intestinal lymphangiectasia (IL) is a protein-losing enteropathy (PLE) characterized by dilation or rupture of intestinal lymphatic vessels, leading to loss of protein-rich lymph into the gastrointestinal lumen. This condition results in hypoalbuminemia, hypoglobulinemia, lymphopenia, and variable clinical signs including chronic diarrhea, weight loss, and peripheral edema. IL can be primary (idiopathic, often congenital) or secondary to diseases that increase lymphatic pressure, such as right-sided congestive heart failure, granulomatous enteritis, or neoplasia. The disorder is most commonly recognized in dogs, particularly in breeds such as the Soft-Coated Wheaten Terrier, Norwegian Lundehund, and Yorkshire Terrier, but can also occur in cats. The pathophysiology involves impaired lymphatic drainage, leading to lacteal dilation, lymphangiectasia, and subsequent loss of lymph into the intestinal lumen. Diagnosis is based on clinical signs, laboratory findings, diagnostic imaging, and histopathology. Treatment focuses on dietary modification, immunosuppression, and management of underlying causes. Prognosis is variable, with some patients achieving long-term remission, while others may have a guarded outcome.

Intestinal lymphangiectasia can be classified as primary (idiopathic) or secondary. Primary IL is often considered congenital or hereditary, with a suspected genetic basis in certain breeds. In Soft-Coated Wheaten Terriers, an autosomal recessive mode of inheritance has been proposed. Secondary IL arises from conditions that increase lymphatic hydrostatic pressure or cause lymphatic obstruction. Common causes include: 1) Right-sided congestive heart failure (e.g., tricuspid valve dysplasia, pulmonary hypertension) leading to increased central venous pressure and impaired lymphatic drainage. 2) Granulomatous enteritis (e.g., fungal infections, foreign body reactions) causing lymphatic obstruction. 3) Intestinal neoplasia, particularly lymphosarcoma, which can infiltrate and obstruct lymphatic vessels. 4) Chronic inflammatory bowel disease (IBD) with severe lymphocytic-plasmacytic enteritis, which may lead to lymphatic inflammation and dilation. 5) Congenital lymphatic abnormalities, such as lymphangiectasia associated with lymphangioma. 6) Rarely, parasitic infections (e.g., severe whipworm infestation) may contribute. The exact molecular triggers are not fully understood, but it is hypothesized that any process that increases intestinal lymphatic pressure or disrupts lymphatic endothelial integrity can lead to the characteristic lacteal dilation and protein loss.

Intestinal lymphangiectasia is most commonly diagnosed in dogs, with a higher prevalence in certain breeds: Soft-Coated Wheaten Terriers (often associated with protein-losing enteropathy and nephropathy), Norwegian Lundehunds (a breed predisposed to gastrointestinal disorders), and Yorkshire Terriers. It can occur in any breed, and there is no strong sex predilection, though some studies suggest a slight female predominance. The age of onset is variable; primary IL may manifest in young to middle-aged dogs (1-5 years), while secondary IL can occur at any age depending on the underlying cause. In cats, IL is less common but can be seen in association with IBD or lymphosarcoma. Geographic distribution is not well-defined, but certain infectious causes (e.g., histoplasmosis) may be more prevalent in specific regions. The incidence is not precisely known, but IL is a significant cause of PLE in dogs, accounting for a substantial proportion of cases. Breed-specific genetic risk factors are being investigated, with genome-wide association studies identifying potential loci in Soft-Coated Wheaten Terriers.

The pathophysiology of intestinal lymphangiectasia involves disruption of the intestinal lymphatic system, leading to loss of lymph into the gut lumen. Normally, intestinal lacteals absorb chylomicrons and lymph from the small intestine. In IL, lymphatic vessels become dilated and may rupture, allowing protein-rich lymph to leak into the intestinal lumen. This results in hypoalbuminemia and hypoglobulinemia, as well as lymphopenia due to loss of lymphocytes into the gut. The loss of immunoglobulins and lymphocytes can lead to immunosuppression, increasing susceptibility to infections. The loss of antithrombin III and other anticoagulant proteins may predispose to thromboembolism. The underlying mechanisms include: 1) Increased lymphatic hydrostatic pressure due to venous hypertension (e.g., right heart failure) or lymphatic obstruction. 2) Primary lymphatic endothelial dysfunction or malformation. 3) Inflammatory mediators that increase vascular permeability and lymphatic permeability. The intestinal mucosa may show villous blunting, lacteal dilation, and infiltration with inflammatory cells. The loss of protein leads to decreased oncotic pressure, resulting in edema and effusions. Malabsorption of fats and fat-soluble vitamins can occur due to lymphatic dysfunction, leading to steatorrhea and deficiencies. The systemic inflammatory response may contribute to further organ dysfunction.

Intrinsic predisposing factors include genetic predisposition, as seen in Soft-Coated Wheaten Terriers and Norwegian Lundehunds. Age may play a role, with primary IL often presenting in young to middle-aged dogs. Extrinsic factors include dietary influences, such as high-fat diets that increase lymphatic flow and pressure, potentially exacerbating lacteal dilation. Concurrent diseases that increase central venous pressure (e.g., heart disease) or cause lymphatic obstruction (e.g., neoplasia, granulomatous disease) are significant risk factors. Immunosuppressive therapy (e.g., corticosteroids) may be used in treatment but can also predispose to secondary infections. Chronic inflammatory bowel disease is a risk factor for secondary IL. Environmental factors such as infectious agents (e.g., Histoplasma, Pythium) can cause granulomatous lymphangitis. Management factors, such as delayed diagnosis, can worsen the condition. Additionally, certain medications (e.g., non-steroidal anti-inflammatory drugs) may exacerbate intestinal inflammation and lymphatic damage.

Clinical signs of intestinal lymphangiectasia are often chronic and progressive. In the early stages, signs may be subtle, including mild intermittent diarrhea and slight weight loss. As the disease progresses, more pronounced signs develop: 1) Chronic diarrhea, often watery or steatorrheic (fatty, foul-smelling, pale stools). 2) Weight loss despite a normal or increased appetite. 3) Peripheral edema (e.g., subcutaneous edema of the limbs, ventral abdomen, or face) due to hypoalbuminemia. 4) Ascites and pleural effusion may occur in severe cases. 5) Lethargy and weakness. 6) Vomiting may be present in some cases. 7) In advanced stages, signs of thromboembolism (e.g., acute dyspnea, neurological signs) may occur. Physical examination may reveal poor body condition, muscle wasting, pale mucous membranes, and evidence of effusions. In some breeds (e.g., Soft-Coated Wheaten Terriers), concurrent protein-losing nephropathy may be present, leading to additional signs such as polyuria and polydipsia. The severity of clinical signs correlates with the degree of protein loss and the underlying cause.

Differential diagnoses for intestinal lymphangiectasia include other causes of protein-losing enteropathy and chronic diarrhea: 1) Inflammatory bowel disease (IBD) – characterized by lymphocytic-plasmacytic or eosinophilic infiltration; may coexist with IL. Key distinguishing features: IBD often responds to immunosuppressive therapy, but IL may require dietary modification; histopathology shows inflammatory infiltrate without significant lacteal dilation. 2) Intestinal lymphosarcoma – neoplastic infiltration of lymphocytes; may cause similar clinical signs and hypoalbuminemia. Diagnosis via full-thickness biopsy showing neoplastic lymphocytes; immunophenotyping (B-cell vs T-cell) helps. 3) Gastrointestinal parasitism (e.g., hookworms, whipworms) – can cause protein loss; fecal flotation and response to anthelmintics. 4) Fungal infections (e.g., histoplasmosis) – may cause granulomatous enteritis and lymphatic obstruction; cytology or histopathology with fungal organisms. 5) Right-sided congestive heart failure – can cause secondary IL; echocardiography reveals cardiac abnormalities. 6) Chronic intestinal intussusception or foreign body – may cause partial obstruction and lymphatic dilation; imaging and exploratory surgery. 7) Exudative enteropathy due to severe ulcerative lesions (e.g., neoplasia, ulcers) – may cause protein loss; endoscopy and biopsy. 8) Hepatic disease (e.g., portosystemic shunt) – can cause hypoalbuminemia but usually with other signs; liver function tests and bile acids. 9) Renal protein-losing nephropathy – may cause hypoalbuminemia; urinalysis with proteinuria and UPC ratio. 10) Exocrine pancreatic insufficiency – causes malabsorption but not typically protein loss; serum TLI test.

The diagnostic approach to intestinal lymphangiectasia should be systematic: 1) Initial assessment: Complete history and physical examination, with attention to body condition, edema, and cardiac evaluation. 2) Baseline laboratory tests: CBC, serum biochemistry (including albumin, globulins, cholesterol, calcium), urinalysis with UPC ratio, and fecal examination. Hypoalbuminemia, hypoglobulinemia, lymphopenia, and hypocholesterolemia are suggestive. 3) If hypoalbuminemia is confirmed, rule out protein-losing nephropathy (UPC > 0.5 in dogs) and hepatic insufficiency (bile acids, ammonia). 4) Thoracic radiographs and echocardiography to evaluate for cardiac disease, especially right-sided heart failure. 5) Abdominal ultrasound: Look for thickened small intestine, hyperechoic mucosal striations (due to lacteal dilation), and mesenteric lymphadenopathy. 6) Serum cobalamin and folate levels may be low due to intestinal malabsorption. 7) Fecal alpha-1-proteinase inhibitor (α1-PI) concentration can confirm protein loss into the gastrointestinal tract; this is a useful test for PLE. 8) Endoscopy with intestinal biopsy: Endoscopic biopsies may show lacteal dilation, but full-thickness biopsies are often needed for definitive diagnosis, especially to rule out lymphosarcoma. 9) Histopathology: Characteristic findings include dilated lacteals, villous blunting, and lymphangiectasia. 10) If secondary causes are suspected, additional tests such as ACTH stimulation for hypoadrenocorticism (which can cause PLE) or specific infectious disease testing (e.g., histoplasmosis antigen) may be indicated. 11) In some cases, lymphangiography or advanced imaging (CT) may be used to visualize lymphatic abnormalities, but these are not routinely performed.

Hematology: Lymphopenia is a common finding due to loss of lymphocytes into the gut. Mild anemia may be present due to chronic disease or blood loss. Serum biochemistry: Hypoalbuminemia is the hallmark, often < 2.0 g/dL. Hypoglobulinemia may also be present. Hypocholesterolemia is common due to malabsorption of lipids. Hypocalcemia may occur due to low albumin (ionized calcium may be normal) or vitamin D malabsorption. Electrolyte imbalances (e.g., hyponatremia, hypokalemia) may occur due to diarrhea. Liver enzymes may be mildly elevated. Urinalysis: If protein-losing nephropathy is concurrent, proteinuria will be present; UPC ratio > 0.5 in dogs is significant. Blood gas analysis: May show metabolic acidosis due to diarrhea. Specific biomarkers: Serum cobalamin (vitamin B12) and folate may be decreased due to intestinal malabsorption. Fecal α1-proteinase inhibitor (α1-PI) concentration is elevated in PLE, confirming gastrointestinal protein loss. Inflammatory markers such as C-reactive protein (CRP) may be elevated. Serology/PCR: If infectious causes are suspected, specific tests (e.g., Histoplasma antigen, parvovirus PCR) may be performed. Endocrine assays: If hypoadrenocorticism is suspected, ACTH stimulation test is indicated.

Radiography: Thoracic radiographs may reveal signs of right-sided heart failure (e.g., cardiomegaly, pleural effusion). Abdominal radiographs may show decreased serosal detail due to ascites. Ultrasonography: Abdominal ultrasound is highly useful. Findings may include: 1) Diffuse thickening of the small intestinal wall, particularly the mucosa. 2) Hyperechoic striations in the mucosa, representing dilated lacteals. 3) Increased echogenicity of the intestinal wall. 4) Mesenteric lymphadenopathy. 5) Ascites. 6) In secondary IL, evidence of underlying disease (e.g., cardiac changes, mass lesions). Doppler ultrasound can assess blood flow but is not specific. Computed Tomography (CT): CT may provide more detailed assessment of intestinal wall thickening and lymphadenopathy, but is not routinely necessary. Magnetic Resonance Imaging (MRI): MRI is rarely used for intestinal evaluation but may be helpful in assessing lymphatic abnormalities. Endoscopy: Endoscopy allows direct visualization of the intestinal mucosa and collection of biopsy samples. Findings may include dilated lacteals (white spots or streaks), mucosal erythema, and friability. Fluoroscopy: Barium contrast studies may show mucosal irregularities but are not specific. Echocardiography: Essential to rule out cardiac causes, especially right-sided heart disease.

Fine Needle Aspirates (FNA): FNA of mesenteric lymph nodes may be performed if lymphadenopathy is present. Cytology may reveal reactive lymphoid hyperplasia or neoplastic lymphocytes (if lymphosarcoma). Fluid analysis: If ascites or pleural effusion is present, fluid analysis typically reveals a modified transudate with low cell count and high protein content (due to protein loss). Histopathology: Definitive diagnosis requires intestinal biopsy. Endoscopic biopsies are often obtained, but full-thickness surgical biopsies are preferred for accurate assessment of lymphatic dilation and to rule out other diseases. Histopathological features of IL include: 1) Dilated lacteals within the villi (lymphangiectasia). 2) Villous blunting and fusion. 3) Mucosal infiltration with lymphocytes and plasma cells (may be mild to moderate). 4) Lipid-laden macrophages in the lamina propria. 5) In secondary IL, evidence of underlying disease (e.g., granulomatous inflammation, neoplastic infiltration). Special stains: Oil Red O can stain lipids in macrophages, but is not routinely used. Immunohistochemistry may be used to differentiate inflammatory cells (e.g., CD3 for T-cells, CD20 for B-cells) if lymphoma is suspected.

Treatment of intestinal lymphangiectasia is multifaceted and aims to reduce lymphatic pressure, manage inflammation, and provide nutritional support. 1) Dietary modification: A highly digestible, low-fat diet is the cornerstone. Fat restriction reduces lymphatic flow and pressure. Medium-chain triglycerides (MCTs) can be used as a calorie source because they are absorbed directly into the portal circulation, bypassing the lymphatics. Commercial low-fat diets or homemade diets with lean protein sources (e.g., boiled chicken, cottage cheese) and carbohydrates (e.g., white rice) are recommended. 2) Immunosuppressive therapy: Corticosteroids (e.g., prednisone) are commonly used to reduce intestinal inflammation. Initial dose: 1-2 mg/kg PO q12h, then tapered over weeks to months. In refractory cases, additional immunosuppressants such as cyclosporine (5-10 mg/kg PO q24h) or azathioprine (2 mg/kg PO q24h) may be added. 3) Management of secondary causes: If an underlying disease is identified (e.g., heart failure, neoplasia), specific treatment is necessary. 4) Supportive care: For hypoalbuminemia, colloids (e.g., hetastarch) may be administered IV in severe cases, but are not a long-term solution. Diuretics (e.g., furosemide) may be used for edema/effusions, but caution is needed to avoid dehydration. 5) Antibiotics: If bacterial overgrowth is suspected, a course of metronidazole (10-15 mg/kg PO q12h) or tylosin (10-20 mg/kg PO q12h) may be beneficial. 6) Vitamin supplementation: Fat-soluble vitamins (A, D, E, K) and cobalamin may be needed due to malabsorption. 7) Antithrombotic therapy: Due to risk of thromboembolism, low-dose aspirin (0.5-1 mg/kg PO q24h) or clopidogrel (1-2 mg/kg PO q24h) may be considered, especially if antithrombin III is low. 8) Surgical intervention: In rare cases of focal lymphatic obstruction (e.g., lymphangioma), surgical resection may be attempted. 9) Emergency stabilization: For severe hypoalbuminemia and effusions, IV colloids and diuretics may be needed. 10) Monitoring: Serial albumin levels and clinical signs guide therapy.

The prognosis for intestinal lymphangiectasia is variable and depends on the underlying cause, severity of protein loss, and response to therapy. In primary IL, with appropriate dietary management and immunosuppression, many dogs achieve remission and maintain a good quality of life for months to years. However, the disease is often chronic and may require lifelong management. In secondary IL, the prognosis depends on the underlying condition; for example, if heart failure is well-controlled, the IL may improve. Negative prognostic indicators include: 1) Severe hypoalbuminemia (< 1.5 g/dL) at diagnosis. 2) Lack of response to dietary modification and immunosuppression within 2-4 weeks. 3) Presence of concurrent protein-losing nephropathy (as in Soft-Coated Wheaten Terriers). 4) Development of thromboembolic complications. 5) Presence of lymphosarcoma (if secondary). Mortality rates are not well-defined, but a significant proportion of dogs may die or be euthanized due to refractory disease or complications. Long-term survival is possible, with some studies reporting median survival times of 1-2 years, but individual outcomes vary widely.

Follow-up care for intestinal lymphangiectasia is essential for monitoring response and adjusting therapy. 1) Re-check appointments: Initially, re-check every 2-4 weeks until clinical signs improve and albumin levels stabilize. 2) Laboratory monitoring: Serial serum albumin, globulins, and electrolytes should be checked at each visit. CBC to monitor for lymphopenia and anemia. 3) Imaging: Repeat abdominal ultrasound may be performed every 3-6 months to assess intestinal changes and lymphadenopathy. 4) Dietary compliance: Reinforce the importance of a strict low-fat diet; avoid high-fat treats. 5) Medication adjustments: Taper immunosuppressive drugs slowly (over months) to the lowest effective dose. Monitor for side effects of corticosteroids (e.g., polyuria, polydipsia, panting). 6) If the patient is on antithrombotic therapy, monitor for bleeding. 7) Long-term monitoring: For dogs with secondary IL, manage the underlying disease (e.g., cardiac medications). 8) Owner education: Warn about signs of relapse (e.g., diarrhea, edema) and the need for prompt veterinary attention. 9) Consider referral to a veterinary nutritionist for dietary planning. 10) In cases of refractory disease, consider advanced therapies such as octreotide (a somatostatin analog) which may reduce lymphatic flow, though evidence is limited.

Pearls: 1) Always rule out protein-losing nephropathy and hepatic insufficiency before diagnosing PLE. 2) Fecal α1-proteinase inhibitor is a valuable test to confirm gastrointestinal protein loss. 3) A low-fat diet is the most critical component of therapy; even small amounts of fat can exacerbate protein loss. 4) In Soft-Coated Wheaten Terriers, screen for concurrent protein-losing nephropathy. 5) Consider hypoadrenocorticism as a cause of PLE; an ACTH stimulation test is indicated in any dog with PLE and no obvious cause. 6) Full-thickness intestinal biopsies are superior to endoscopic biopsies for diagnosing IL and ruling out lymphoma. 7) Monitor antithrombin III levels; if low, consider antithrombotic therapy. 8) Cobalamin supplementation is often needed; injectable cobalamin (250-500 μg SC q7d for 6 weeks, then monthly) is effective. Pitfalls: 1) Failing to perform a thorough cardiac evaluation, missing right-sided heart failure as a cause. 2) Using a high-fat diet or not enforcing dietary restrictions strictly. 3) Tapering immunosuppressive drugs too quickly, leading to relapse. 4) Overlooking the possibility of concurrent exocrine pancreatic insufficiency (EPI); a serum TLI test should be performed. 5) Assuming that hypoalbuminemia is solely due to gastrointestinal loss without ruling out other causes. 6) Not considering thromboembolism as a complication; sudden dyspnea or neurological signs should prompt immediate evaluation. 7) Using diuretics aggressively, which can worsen dehydration and electrolyte imbalances. 8) Delaying biopsy, leading to progression of disease.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used: 1) Prednisone: 1-2 mg/kg PO q12h for 2-4 weeks, then taper by 25% every 2-4 weeks to the lowest effective dose (often 0.5 mg/kg q48h). If no response in 2 weeks, consider adding another immunosuppressant. 2) Cyclosporine (modified): 5-10 mg/kg PO q24h. Monitor blood levels (target 400-600 ng/mL) if possible. 3) Azathioprine: 2 mg/kg PO q24h for 2-4 weeks, then q48h. Monitor CBC for myelosuppression. 4) Metronidazole: 10-15 mg/kg PO q12h for 2-4 weeks. 5) Tylosin: 10-20 mg/kg PO q12h with food. 6) Cobalamin (vitamin B12): 250-500 μg SC q7d for 6 weeks, then monthly. 7) Fat-soluble vitamins: Vitamin E (10-20 IU/kg PO q24h), Vitamin D (as directed), Vitamin K1 (if deficiency). 8) Hetastarch (6%): 20 ml/kg IV over 6-8 hours for severe hypoalbuminemia, but use with caution in heart disease. 9) Furosemide: 1-2 mg/kg PO q12h for effusions, but monitor renal function and electrolytes. 10) Aspirin: 0.5-1 mg/kg PO q24h for antithrombotic effect. 11) Clopidogrel: 1-2 mg/kg PO q24h. 12) Octreotide: 10-20 μg/kg SC q8h (limited evidence, but may reduce lymphatic flow). 13) For secondary causes, specific drugs (e.g., pimobendan for heart failure) should be used. Always adjust dosages for renal or hepatic impairment, and monitor for drug interactions.

Key studies and consensus guidelines: 1) A study by Kimmel et al. (2000) evaluated 30 dogs with PLE and found that hypoalbuminemia and lymphopenia were common, and that dietary modification and immunosuppression led to improvement in many cases. 2) A retrospective study by Craven et al. (2004) reported that dogs with IL had a median survival time of 2.5 years, with poor prognostic indicators including severe hypoalbuminemia and lack of response to therapy. 3) The ACVIM consensus statement on the diagnosis and treatment of chronic inflammatory bowel disease (2010) includes IL as a differential and recommends full-thickness biopsies for definitive diagnosis. 4) A study by Littman et al. (2000) on Soft-Coated Wheaten Terriers highlighted the genetic predisposition and concurrent protein-losing nephropathy. 5) A study by Willard et al. (2009) evaluated the use of fecal α1-proteinase inhibitor as a diagnostic test for PLE, showing high sensitivity and specificity. 6) A study by Okanishi et al. (2015) investigated the use of octreotide in dogs with IL, showing some benefit in reducing protein loss. 7) The ECVIM consensus on protein-losing enteropathy (2016) recommends a stepwise diagnostic approach and emphasizes the importance of dietary fat restriction. 8) A recent study by Dossin et al. (2019) evaluated the use of cyclosporine in dogs with PLE, showing efficacy in some cases. 9) A study by Nakazawa et al. (2018) investigated the role of intestinal lymphangiectasia in cats, noting an association with lymphoma. 10) The IRIS guidelines for proteinuria are relevant when concurrent nephropathy is suspected. Overall, evidence supports a combination of dietary management and immunosuppression, with careful monitoring for complications.